Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...

Indraprastha Apollo Hospitals proudly announces the launch of its Heart Valve Clinic, a dedicated facility designed to ...

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...

The first human TAVR was performed by Dr. Cribier in 2002. [33] There have been three generations of the Cribier-Edwards SAPIEN valve. The only valve that has FDA approval is the Edwards SAPIEN ...

Baptist Health Paducah is celebrating after achieving recertification in transcatheter valve repair and replacement (TAVR) from the American College of Cardiology. In a news release, Baptist ...

Self-expanding valves (SEVs) are associated with less prosthesis-patient mismatch (PPM) in East Asian patients with small aortic annuli (SAA) undergoing TAVR, compared with balloon-expandable valves ...

With a portfolio of services including advanced imaging and minimally invasive procedures, the clinic employs innovative methods such as Transcatheter Aortic Valve Replacement (TAVR) and robotic ...

The Trilogy valve. [Image from the JenaValve website] GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) this year.